Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial Article Early Access

cited authors

  • Valabrega, Giorgio; Powell, Matthew A.; Hietanen, Sakari; Miller, Eirwen M.; Novak, Zoltan; Holloway, Robert; Denschlag, Dominik; Myers, Tashanna; Thijs, Anna M.; Pennington, Kathryn P.; Gilbert, Lucy; Fleming, Evelyn; Zub, Oleksandr; Landrum, Lisa M.; Ataseven, Beyhan; Gogoi, Radhika; Podzielinski, Iwona; Cloven, Noelle; Monk, Bradley J.; Sharma, Sudarshan; Herzog, Thomas J.; Stuckey, Ashley; Pothuri, Bhavana; Secord, Angeles Alvarez; Chase, Dana; Vincent, Veena; Meyers, Oren; Garside, Jamie; Mirza, Mansoor Raza; Black, Destin

Publication Date

  • September 25, 2024

webpage

published in

category

keywords

  • Uterine Cancer
  • Uterus